Oct 2, 2018
GUYS
GUYS GUYS
KEYTRUDA GOT THE NOBEL PRIZE
seen from Netherlands
seen from Hungary
seen from Tunisia
seen from Germany
seen from United States
seen from United States
seen from Canada
seen from China
seen from France
seen from Germany
seen from Germany
seen from United States
seen from Mexico
seen from Canada
seen from Malaysia
seen from United States
seen from China
seen from China
seen from Germany
seen from China
GUYS
GUYS GUYS
KEYTRUDA GOT THE NOBEL PRIZE
A recent study published in the journal Nature Medicine suggests that a specific type of immunotherapy may be effective in treating advanced lung cancer. The study found that patients who received a combination of two drugs, nivolumab and ipilimumab, had a higher survival rate compared to those who received only one of the drugs or […]
New Immunotherapy Treatment Shows Promise for Advanced Lung Cancer #advancedlungcancer #immunotherapy #ipilimumab #lungcancertreatment #nivolumab
Ipilimumab (Mechanism of Action)
Ipilimumab (Mechanism of Action)
In this article, we will discuss Ipilimumab (Mechanism of Action). So, let’s get started. Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an IgG1 kappa immunoglobulin with an approximate molecular weight of 148 kDa. Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture. Ipilimumab…
View On WordPress
Ipilimumab
In this article, we will discuss about Ipilimumab (Dosage). So, let’s get started. IndicationsUnresectable or Metastatic MelanomaIpilimumab (YERVOY) is indicated for the treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older).Adjuvant Treatment of MelanomaIpilimumab (YERVOY) is indicated for the adjuvant treatment of patients with cutaneous melanoma…
View On WordPress
Merck presents results from head-to-head Phase 3 KEYNOTE-598 Trial evaluating KEYTRUDA® (pembrolizumab) in combination with ipilimumab versus KEYTRUDA Monotherapy in certain patients with metastatic non-small cell lung cancer
Merck presents results from head-to-head Phase 3 KEYNOTE-598 Trial evaluating KEYTRUDA® (pembrolizumab) in combination with ipilimumab versus KEYTRUDA Monotherapy in certain patients with metastatic non-small cell lung cancer
Findings Presented in World Conference on Lung Cancer 2020 Presidential Symposium and Published in the Journal of Clinical Oncology KENILWORTH, N.J. — (BUSINESS WIRE) — $MRK #MRK— Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data from the Phase 3 KEYNOTE-598 study evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with ipilimumab…
View On WordPress
Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than pembrolizumab alone as first-line therapy for metastatic non-small cell lung cancer (NSCLC) for patients with a PD-L1 tumor proportion score of greater than or equal to 50% and no targetable EGFR or ALK aberrations, according to research presented today at the International Association for…
View On WordPress